| Li-Fraumeni Syndrome (predicted) |
| Geno
|
Mag
|
Summary
|
| (A;G)
|
7
|
Li-Fraumeni Syndrome (predicted)
|
| (C;C)
|
0
|
|
| (G;G)
|
0
|
common in clinvar
|
| (G;T)
|
7
|
Li-Fraumeni Syndrome (predicted)
|
This is a genotype with recommended actions if clinically confirmed. In brief:
- Based on mutations in the TP53 gene, Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome associated with early onset of multiple primary neoplasms.
- LFS is highly penetrant with a high lifetime risk for cancer.
- The screening and management of LFS is complex. It is preferred that individuals with LFS be followed at centers with expertise in the management of this syndrome.
- Annual surveillance with breast MRI should be offered to women aged 20-49 years, and should be considered for women aged 50-69. Other cancers are harder to detect early and a wide variety of surveillance recommendations are available.
- Carriers of TP53 pathogenic variants are counseled to avoid sun exposure, tobacco use, and other known or suspected carcinogens.
The full ClinGen Actionability report about Li-Fraumeni Syndrome (LFS) can be found
here.
Genetic counseling may be available to you through your health-care network. In the US, genetic counselors may be found via this webpage of the National Society of Genetic Counselors.
